Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 9/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112796 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNAKMT2AATMMEN1 | |
| SCHEMBL4107182 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAKMT2AATMMEN1 | |
| SCHEMBL4107178 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAKMT2AATMMEN1 | |
| SCHEMBL4113520 | 0.73 | ATM (0.54) | KMT2AATMMAPT | |
| SCHEMBL28576320 | 0.73 | ATM (0.54) | KMT2AATMMAPT | |
| SCHEMBL15797717 | 0.70 | CA12 (0.51) | SMN1; SMN2LMNAKMT2AATMMEN1 | |
| SCHEMBL15797772 | 0.70 | CA12 (0.51) | SMN1; SMN2LMNAKMT2AATMMEN1 | |
| SCHEMBL1532533 | 0.70 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAKMT2AATMMEN1 | |
| SCHEMBL15805563 | 0.69 | MAPT (0.56) | SMN1; SMN2LMNAKMT2AATMMEN1 | |
| SCHEMBL28608616 | 0.69 | ATM (0.71) | ATMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047223-A1 | Improvements in or Related to Organic Compoounds | GIVAUDAN SA (CH) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047223-A1 | Improvements in or Related to Organic Compoounds | LPO, OTC, OAT | SMN1; SMN2 1471/4885LMNA 4030/4885KMT2A 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.